Untreated and Staurosporine treated Jurkat cells were subjected to SDS PAGE followed by western blot with 10380-1-AP (Caspase 9/p35/p10 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

Immunohistochemical analysis of paraffin-embedded human heart tissue slide using 10380-1-AP (Caspase 9/p35/p10 antibody) at dilution of 1:50 (under 10x lens).

Immunohistochemical analysis of paraffin-embedded human heart tissue slide using 10380-1-AP (Caspase 9/p35/p10 antibody) at dilution of 1:50 (under 40x lens).

IP result of anti-Caspase 9/p35/p10 (IP:10380-1-AP, 3ug; Detection:10380-1-AP 1:200) with HeLa cells lysate 2500 ug.

Immunofluorescent analysis of (-20℃ Ethanol) fixed HepG2 cells using 10380-1-AP (Caspase 9/p35/p10 antibody) at dilution of 1:50 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

1X10^6 HepG2 cells were stained with 0.2ug Caspase 9/p35/p10 antibody (10380-1-AP, red) and control antibody (blue). Fixed with 90% MeOH blocked with 3% BSA (30 min). Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) with dilution 1:1000.

Untreated and Staurosporine treated Jurkat cells were subjected to SDS PAGE followed by western blot with 66169-1-Ig (Caspase 9/p35/p10 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

HeLa cells were subjected to SDS PAGE followed by western blot with 66169-1-Ig (Caspase 9/p35/p10 antibody at dilution of 1:1000 incubated at room temperature for 1.5 hours.

IP result of anti-Caspase 9/p35/p10 (IP:66169-1-Ig, 5ug; Detection:66169-1-Ig 1:500) with HeLa cells lysate 3200ug.

Immunohistochemical analysis of paraffin-embedded human lymphoma tissue slide using 66169-1-Ig (Caspase 9/p35/p10 antibody at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

Immunohistochemical analysis of paraffin-embedded human lymphoma tissue slide using 66169-1-Ig (Caspase 9/p35/p10 antibody at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

Immunofluorescent analysis of (-20℃ Ethanol ) fixed HeLa cells using 66169-1-Ig(Caspase 9/p35/p10 antibody) at dilution of 1:100 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).

Untreated and Staurosporine treated Jurkat cells were subjected to SDS PAGE followed by western blot with 66169-1-Ig (Caspase 9/p35/p10 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 66169-1-PBS in a different storage buffer formulation.

HeLa cells were subjected to SDS PAGE followed by western blot with 66169-1-Ig (Caspase 9/p35/p10 antibody at dilution of 1:1000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 66169-1-PBS in a different storage buffer formulation.

IP result of anti-Caspase 9/p35/p10 (IP:66169-1-Ig, 5ug; Detection:66169-1-Ig 1:500) with HeLa cells lysate 3200ug. This data was developed using the same antibody clone with 66169-1-PBS in a different storage buffer formulation.

Immunohistochemical analysis of paraffin-embedded human lymphoma tissue slide using 66169-1-Ig (Caspase 9/p35/p10 antibody at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 66169-1-PBS in a different storage buffer formulation.

Immunohistochemical analysis of paraffin-embedded human lymphoma tissue slide using 66169-1-Ig (Caspase 9/p35/p10 antibody at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 66169-1-PBS in a different storage buffer formulation.

Immunofluorescent analysis of (-20℃ Ethanol ) fixed HeLa cells using 66169-1-Ig(Caspase 9/p35/p10 antibody) at dilution of 1:100 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG(H+L). This data was developed using the same antibody clone with 66169-1-PBS in a different storage buffer formulation.

Non-treated HEK-293T and calyculin A treated HEK-293T cells were subjected to SDS PAGE followed by western blot with 28794-1-AP (Phospho-Caspase 9 (Ser196) antibody) at dilution of 1:2000 incubated at 4℃ overnight. The membrane was stripped and re-blotted with GAPDH antibody as loading control.

Immunofluorescent analysis of (-20°C Ethanol) fixed HeLa cells using CoraLite® Plus 488 Caspase 9/p35/p10 antibody (CL488-66169, Clone: 1B7G2 ) at dilution of 1:200.

1X10^6 HepG2 cells were intracellularly stained with 0.4 ug CoraLite® Plus 488 Anti-Human Caspase 9/p35/p10 (CL488-66169, Clone:1B7G2) (red), or 0.4 ug Mouse IgG2b Isotype Control (CL488-66360-3, Clone: K11B8C4B5) (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

1X10^6 HepG2 cells were intracellularly stained with 0.4 ug CoraLite®488 Anti-Human Caspase 9/p35/p10 (CL488-10380) (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

1X10^6 HEK-293 cells untreated (dashed lines) or treated with Calyculin A (red) were intracellularly stained with 0.13 ug CoraLite®488 Anti-Human Phospho-Caspase 9 (Ser196) (CL488-80346, Clone:3P16) , or 0.13 ug Control Antibody (blue). Cells were fixed with 4% PFA and permeabilized with 80% MeOH.

1X10^6 HepG2 cells were intracellularly stained with 0.2 ug CoraLite® Plus 647 Anti-Human Caspase 9/p35/p10 (CL647-10380) (red), or 0.2 ug Isotype Control (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).